178 related articles for article (PubMed ID: 21422404)
1. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
Smith BD
J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
[No Abstract] [Full Text] [Related]
2. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
Franceschino A; Tornaghi L; Piazza R; Pogliani E; Gambacorti Passerini C
Haematologica; 2006 Jun; 91(6 Suppl):ECR14. PubMed ID: 16785120
[No Abstract] [Full Text] [Related]
3. Current use of imatinib in the treatment of chronic myeloid leukemia.
O'Dwyer M
Haematologica; 2003 Mar; 88(3):241-4. PubMed ID: 12651257
[No Abstract] [Full Text] [Related]
4. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
Cashen A; DiPersio JF; Khoury H
J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
[No Abstract] [Full Text] [Related]
5. Practical management of patients with chronic myeloid leukemia receiving imatinib.
Deininger MW; O'Brien SG; Ford JM; Druker BJ
J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
[TBL] [Abstract][Full Text] [Related]
6. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital.
Reksodiputro AH; Syafei S; Prayogo N; Karsono B; Rinaldi I; Rajabto W; Mulansari NA
Acta Med Indones; 2010 Jan; 42(1):2-5. PubMed ID: 20305324
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
9. [Chronic myeloid leukemia].
Hochhaus A
Dtsch Med Wochenschr; 2011 Oct; 136(40):2007-10. PubMed ID: 21960328
[No Abstract] [Full Text] [Related]
10. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Jabbour E; Cortes J; Kantarjian H
Oncology (Williston Park); 2007 May; 21(6):653-62; discussion 663-4, 667-8. PubMed ID: 17564324
[TBL] [Abstract][Full Text] [Related]
11. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
Hochhaus A
Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
[No Abstract] [Full Text] [Related]
12. [Management of chronic myeloid leukemia by imatinib].
Kizaki M
Rinsho Ketsueki; 2010 Oct; 51(10):1377-85. PubMed ID: 20962470
[No Abstract] [Full Text] [Related]
13. Imatinib therapy in chronic myeloid leukemia.
Crossman LC; O'Brien SG
Hematol Oncol Clin North Am; 2004 Jun; 18(3):605-17, viii. PubMed ID: 15271395
[TBL] [Abstract][Full Text] [Related]
14. Current status of imatinib as frontline therapy for chronic myeloid leukemia.
Marin D
Semin Hematol; 2010 Oct; 47(4):312-8. PubMed ID: 20875547
[TBL] [Abstract][Full Text] [Related]
15. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
16. [STI571: a new dimension in the treatment of chronic myeloid leukemia].
Somers JA; Shamelian SO; Löwenberg B; Ossenkoppele GJ; Cornelissen JJ
Ned Tijdschr Geneeskd; 2002 Jan; 146(3):128-32. PubMed ID: 11826673
[TBL] [Abstract][Full Text] [Related]
17. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
19. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
[TBL] [Abstract][Full Text] [Related]
20. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
Ajima A; Takayama N; Hasegawa Y; Kojima H; Nagasawa T
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1997-9. PubMed ID: 14650975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
